AgingResearch.NewsJoin free

Catalent

CompanyUnited States

Catalent develops one asset, in human trials (GS010 in Leber hereditary optic neuropathy). Mostly gene therapy acting on oxidative phosphorylation and MT-ND4; based in the United States.

1
Asset
Furthest stage
Human trials
0
Trials
1
Signal

Pipeline

1

  • GS010

    AAV2 gene therapy expressing ND4 targeting mitochondrial complex I to restore visual function.

    Human trials, Gene therapy, Oxidative phosphorylation, MT-ND4, Leber hereditary optic neuropathy, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Signals1
  • Similar companies6

Intelligence